Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWhat the Evidence Actually Says: Tesamorelin and Tirzepatide Side by Side
The biggest misconception: these two medicines target the same problem
People arrive at this comparison after reading that tesamorelin can reduce visceral (abdominal) fat, and assuming it must therefore be a general weight-loss treatment competing with Mounjaro. That reading is understandable, but it overstates what tesamorelin does and who it is for.
Tesamorelin stimulates the pituitary gland to release growth hormone. In people living with HIV who have developed lipodystrophy (a condition where antiretroviral therapy disrupts fat distribution, typically causing excess abdominal fat) tesamorelin has been shown to reduce visceral fat meaningfully. That is the indication it was developed and studied for. It is not licensed in the UK for obesity, overweight, or general weight management, and it is not available through a weight-loss clinic here. A question our prescribers hear most weeks is whether a medicine they've read about online is the same as, or interchangeable with, Mounjaro; tesamorelin is a clear example of a drug whose niche indication gets lost in translation.
Tirzepatide works through an entirely different mechanism: it activates two gut-hormone receptors simultaneously (GIP and GLP-1) which together reduce appetite, slow gastric emptying, and influence how the body handles calories. It is the only dual-agonist weight-management medicine licensed in the UK, and if you are weighing up how tirzepatide compares to Mounjaro as a branded product, our dedicated page explains the relationship between the two clearly. You can read more about how it works on our Mounjaro overview page.
How they compare on the things that matter for weight management
The table below draws on published clinical evidence and UK licensing information. Because tesamorelin is not licensed for general weight management, this is not a head-to-head comparison of equals; it is a factual account of what each medicine is studied and authorised to do.
| Factor | Tirzepatide (Mounjaro) | Tesamorelin |
|---|---|---|
| UK licence for weight management | Yes (adults, BMI ≥30 or ≥27 with a weight-related condition | No) licensed for HIV-associated lipodystrophy |
| Mechanism | Dual GIP and GLP-1 receptor agonist | Growth hormone-releasing factor analogue |
| Average weight reduction in trials | Around 20–21% body weight at 15 mg over 72 weeks [SURMOUNT-1, NEJM] | Significant visceral fat reduction in HIV lipodystrophy; not studied for generalised obesity |
| Route and frequency | Once-weekly subcutaneous injection (KwikPen) | Daily subcutaneous injection |
| Available through UK weight-loss services | Yes, via private prescription or NHS pathway | No |
| NICE appraisal for weight management | Yes — TA1026, published December 2024 [NICE TA1026] | No appraisal exists for this indication |
If you are living with HIV and have been told about lipodystrophy, tesamorelin is a conversation for your HIV specialist, not a weight-loss clinic. If your goal is managing weight or a weight-related condition such as hypertension or obstructive sleep apnoea, our page covering the differences between tirzepatide and Manjaro can help you understand the terminology before you explore the licensed option further. You can compare tirzepatide against other agents in our GLP-1 vs tirzepatide overview.
Eligibility and safety: what applies to tirzepatide in the UK
Because tesamorelin sits outside the weight-management landscape, the eligibility and safety discussion here concerns tirzepatide. The licensed eligibility criteria are: adult age, BMI of 30 or above, or 27 or above with at least one weight-related condition. Lower BMI thresholds apply for certain ethnic backgrounds under UK guidance. NICE's independent appraisal sets a slightly narrower bar for NHS access (BMI 35 or above with at least one comorbidity) whereas private prescribing follows the licensed indication directly. The NHS rollout is phased, and the weight management treatment overview covers the current access picture plainly.
Tirzepatide's most common side effects are gastrointestinal: nausea tends to peak in the first days after a new dose, diarrhoea and constipation can alternate, and indigestion is common early on. These typically ease as the body adjusts. Severe, persistent stomach pain radiating to the back is a signal to seek urgent medical help given the known risk of acute pancreatitis with GLP-1 class medicines, highlighted in a January 2026 MHRA Drug Safety Update. The NHS tirzepatide medicines page lists the full side-effect profile with clear guidance on when to call 111 or 999.
Tirzepatide is not recommended in pregnancy, during breastfeeding, or when actively trying to conceive. It is not licensed for under-18s. People with a history of certain thyroid cancers or pancreatitis should discuss this with a prescriber. Contraception note: women using oral contraceptives should add a barrier method for the first four weeks of treatment and for four weeks after each dose increase, because the pill's absorption may be reduced.
What this means if you're exploring your options
If someone has pointed you towards tesamorelin as a Mounjaro alternative, the short answer is that it is not an alternative in a UK weight-management context. It does a specific job for a specific population, and it is not available through general prescribing services here. For a broader sense of where tirzepatide sits among newer investigational agents, our page on retatrutide versus tirzepatide covers the pipeline honestly, and the Mounjaro cost context page gives a clear account of private treatment pricing.
Which medicine is right for you (if any) is a clinical decision that belongs with a prescriber who knows your health history. Our clinical team, led by our clinical director, reviews every consultation personally. Start your free consultation to have that conversation properly.
Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.